September 20, 2020 | English | عربي
   Add to Twitter
 
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health
• Boehringer Ingelheim joins forces with Belgian biotech company GST which develops and produces state-of-the art stem cell products for horses and pets

• The acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European market

• Decision to acquire GST is fully aligned with part of Boehringer Ingelheim’s Animal Health strategy, aiming to strengthen its portfolio capabilities to accelerate innovation and growth